Compass Therapeutics, Inc. (NASDAQ:CMPX) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT
Company Participants
Thomas Schuetz – CEO & Vice Chairman
Barry Shin – Chief Financial Officer
Conference Call Participants
Kelly McCarthy
Presentation
Kelly McCarthy
Good afternoon, everyone. This is Kelly McCarthy from the Morgan Stanley Healthcare team, and it’s great to be here with the management team of Compass Therapeutics. I’m joined by CEO, Tim Schuetz (sic) [ Tom Schuetz ]; and CFO, Barry Shin. So thank you both for coming. Hopefully, it’s been a productive conference for you so far.
Before I get into the Compass Therapeutics’ story, I’m just going to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Question-and-Answer Session
Kelly McCarthy
So Tom, let’s start with you. For those who may be less familiar with the Compass Therapeutics’ story, can you give a little bit of company history and just how your pipeline kind of came together?
Thomas Schuetz
CEO & Vice Chairman
Sure. And thanks, Kelly, and thanks to Morgan Stanley for inviting us to the conference. And I would also echo the disclosure, frankly, I will be making forward-looking statements today, and I would refer anyone to our regulatory disclosures for risks associated with those.
So again, thank you. So Compass, we’re located in Boston, Mass. We’re a monoclonal antibody development and discovery company in oncology. So we have 3 drugs in the clinic, 2 bispecific antibodies and 1 monoclonal antibody, and we have a fourth drug that we’ll be filing an IND for in the next quarter.
So our lead program is a DLL4 VEGF-A bispecific antibody called tovecimig. We announced earlier this
#Compass #Therapeutics #CMPX #Morgan #Stanley #23rd #Annual #Global #Healthcare #Transcript